vs

Side-by-side financial comparison of PURE CYCLE CORP (PCYO) and Protalix BioTherapeutics, Inc. (PLX). Click either name above to swap in a different company.

PURE CYCLE CORP is the larger business by last-quarter revenue ($9.1M vs $9.1M, roughly 1.0× Protalix BioTherapeutics, Inc.). PURE CYCLE CORP runs the higher net margin — 50.0% vs -60.3%, a 110.3% gap on every dollar of revenue. On growth, PURE CYCLE CORP posted the faster year-over-year revenue change (58.8% vs -49.9%). Over the past eight quarters, PURE CYCLE CORP's revenue compounded faster (69.0% CAGR vs -6.7%).

Pure Cycles, is a bicycle company based in Los Angeles, California that was founded by Michael Fishman, Jordan Schau, Zachary Schau and Austin Stoffers in 2010, as Pure Fix Cycles.

Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.

PCYO vs PLX — Head-to-Head

Bigger by revenue
PCYO
PCYO
1.0× larger
PCYO
$9.1M
$9.1M
PLX
Growing faster (revenue YoY)
PCYO
PCYO
+108.7% gap
PCYO
58.8%
-49.9%
PLX
Higher net margin
PCYO
PCYO
110.3% more per $
PCYO
50.0%
-60.3%
PLX
Faster 2-yr revenue CAGR
PCYO
PCYO
Annualised
PCYO
69.0%
-6.7%
PLX

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
PCYO
PCYO
PLX
PLX
Revenue
$9.1M
$9.1M
Net Profit
$4.6M
$-5.5M
Gross Margin
68.4%
49.4%
Operating Margin
48.0%
-51.1%
Net Margin
50.0%
-60.3%
Revenue YoY
58.8%
-49.9%
Net Profit YoY
16.0%
-184.8%
EPS (diluted)
$0.19
$-0.06

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PCYO
PCYO
PLX
PLX
Q4 25
$9.1M
$9.1M
Q3 25
$11.2M
$17.9M
Q2 25
$5.1M
$15.7M
Q1 25
$4.0M
$10.1M
Q4 24
$5.8M
$18.2M
Q3 24
$12.6M
$18.0M
Q2 24
$7.6M
$13.5M
Q1 24
$3.2M
Net Profit
PCYO
PCYO
PLX
PLX
Q4 25
$4.6M
$-5.5M
Q3 25
$6.1M
$2.4M
Q2 25
$2.3M
$164.0K
Q1 25
$809.0K
$-3.6M
Q4 24
$3.9M
$6.5M
Q3 24
$6.6M
$3.2M
Q2 24
$2.8M
$-2.2M
Q1 24
$118.0K
Gross Margin
PCYO
PCYO
PLX
PLX
Q4 25
68.4%
49.4%
Q3 25
67.7%
53.4%
Q2 25
63.4%
62.5%
Q1 25
38.2%
19.1%
Q4 24
63.8%
78.7%
Q3 24
77.8%
53.4%
Q2 24
64.0%
29.8%
Q1 24
55.6%
Operating Margin
PCYO
PCYO
PLX
PLX
Q4 25
48.0%
-51.1%
Q3 25
53.1%
11.9%
Q2 25
26.0%
7.5%
Q1 25
-33.2%
-41.0%
Q4 24
29.9%
39.6%
Q3 24
62.0%
22.2%
Q2 24
40.3%
-18.0%
Q1 24
-11.5%
Net Margin
PCYO
PCYO
PLX
PLX
Q4 25
50.0%
-60.3%
Q3 25
54.5%
13.2%
Q2 25
43.9%
1.0%
Q1 25
20.3%
-35.8%
Q4 24
68.4%
35.6%
Q3 24
52.6%
18.0%
Q2 24
37.2%
-16.4%
Q1 24
3.7%
EPS (diluted)
PCYO
PCYO
PLX
PLX
Q4 25
$0.19
$-0.06
Q3 25
$0.26
$0.03
Q2 25
$0.09
$0.00
Q1 25
$0.03
$-0.05
Q4 24
$0.16
$0.10
Q3 24
$0.27
$0.03
Q2 24
$0.12
$-0.03
Q1 24
$0.00

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PCYO
PCYO
PLX
PLX
Cash + ST InvestmentsLiquidity on hand
$17.1M
$14.7M
Total DebtLower is stronger
$8.0M
Stockholders' EquityBook value
$147.5M
$48.2M
Total Assets
$168.1M
$82.3M
Debt / EquityLower = less leverage
0.05×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PCYO
PCYO
PLX
PLX
Q4 25
$17.1M
$14.7M
Q3 25
$21.9M
$13.6M
Q2 25
$14.4M
$17.9M
Q1 25
$16.5M
$19.5M
Q4 24
$19.0M
$19.8M
Q3 24
$22.1M
$27.4M
Q2 24
$20.5M
$23.4M
Q1 24
$20.6M
Total Debt
PCYO
PCYO
PLX
PLX
Q4 25
$8.0M
Q3 25
$6.8M
Q2 25
$6.9M
Q1 25
$6.9M
Q4 24
$6.9M
Q3 24
$6.9M
Q2 24
Q1 24
Stockholders' Equity
PCYO
PCYO
PLX
PLX
Q4 25
$147.5M
$48.2M
Q3 25
$142.7M
$52.9M
Q2 25
$136.7M
$49.9M
Q1 25
$134.4M
$45.2M
Q4 24
$133.6M
$43.2M
Q3 24
$129.7M
$32.4M
Q2 24
$123.2M
$28.6M
Q1 24
$120.4M
Total Assets
PCYO
PCYO
PLX
PLX
Q4 25
$168.1M
$82.3M
Q3 25
$162.3M
$82.3M
Q2 25
$151.7M
$78.5M
Q1 25
$149.7M
$73.9M
Q4 24
$149.7M
$73.4M
Q3 24
$147.4M
$61.6M
Q2 24
$140.4M
$91.5M
Q1 24
$135.2M
Debt / Equity
PCYO
PCYO
PLX
PLX
Q4 25
0.05×
Q3 25
0.05×
Q2 25
0.05×
Q1 25
0.05×
Q4 24
0.05×
Q3 24
0.05×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PCYO
PCYO
PLX
PLX
Operating Cash FlowLast quarter
$-979.0K
$2.0M
Free Cash FlowOCF − Capex
$1.6M
FCF MarginFCF / Revenue
17.8%
Capex IntensityCapex / Revenue
4.4%
Cash ConversionOCF / Net Profit
-0.21×
TTM Free Cash FlowTrailing 4 quarters
$-13.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PCYO
PCYO
PLX
PLX
Q4 25
$-979.0K
$2.0M
Q3 25
$9.4M
$-3.7M
Q2 25
$-503.0K
$-5.2M
Q1 25
$-1.4M
$-5.1M
Q4 24
$5.7M
$4.0M
Q3 24
$3.1M
$4.1M
Q2 24
$892.0K
$-3.6M
Q1 24
$-457.0K
Free Cash Flow
PCYO
PCYO
PLX
PLX
Q4 25
$1.6M
Q3 25
$-4.2M
Q2 25
$-5.7M
Q1 25
$-5.4M
Q4 24
$3.6M
Q3 24
$4.0M
Q2 24
$-3.8M
Q1 24
FCF Margin
PCYO
PCYO
PLX
PLX
Q4 25
17.8%
Q3 25
-23.7%
Q2 25
-36.2%
Q1 25
-53.0%
Q4 24
19.6%
Q3 24
22.4%
Q2 24
-28.1%
Q1 24
Capex Intensity
PCYO
PCYO
PLX
PLX
Q4 25
4.4%
Q3 25
2.8%
Q2 25
2.8%
Q1 25
3.0%
Q4 24
2.3%
Q3 24
0.5%
Q2 24
1.3%
Q1 24
Cash Conversion
PCYO
PCYO
PLX
PLX
Q4 25
-0.21×
Q3 25
1.53×
-1.58×
Q2 25
-0.22×
-31.91×
Q1 25
-1.70×
Q4 24
1.44×
0.61×
Q3 24
0.47×
1.27×
Q2 24
0.32×
Q1 24
-3.87×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

PCYO
PCYO

Construction$6.5M71%
Water And Wastewater Resource Development Segment$2.5M27%

PLX
PLX

Products$8.7M95%
Other$428.0K5%

Related Comparisons